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392 Brave lung: non invasive ventilation (NIV) and pneumothorax
S. Gambazza1, S. Bresci2, D. Innocenti1, S. Marchi2, A.S. Neri1, S. Zuffo1,
C. Braggion1. 1Azienda Ospedaliera Universitaria Meyer, Cystic Fibrosis Centre,
Pediatric Department, Firenze, Italy; 2Azienda Ospedaliera Universitaria Careggi,
Infectious Disease, Firenze, Italy
Hypercapnic respiratory failure and recurrent pneumothorax (pnx) in severe cystic
ﬁbrosis (CF) requires ad hoc evaluation and ventilatory management. Pnx is a
relative contraindication to NIV so its use is not encouraged if pulmonary bubbles
and medical history of past pnx are described.
The patient is a 26 yo male with severe lung disease (FEV1 20−30% pred.) in
nocturnal oxygen therapy (OT) at NIV start. Clinical history is characterised by
malnutrition with PEG for enteral feeding, chronic airway infection by P. aeruginosa
and MRSA, sinusopathy and depressive syndrome. In 1999 he had recurrent left
pnx treated with pleurodesis and a right one ten yrs after drained and talced. A
fall in lung function resulting in symptomatic hypoxaemia-hypercapnia, persistent
during exacerbations, followed the last pnx. Though large bubbles all through the
superior right lobe on CT Thorax, we gradually initiated him to NIV with nasal
mask, IPAP and EPAP 11−4 cmH2O in spontaneous mode. BGA motivated us to go
on so we acclimatised him to night NIV with OT 1L/min. NIV was well tolerated
with disappearance of morning headache, somnolence and better quality of sleep.
After a month, IPAP was set at 15 cmH2O and awakening BGA revealed better
PaO2 and stable CO2. After 6 months, BGA improved more: awakening CO2 was
yet ~50mmHg and PaO2 was fair; CT follow-up did not change. Adherence showed
100% of use for 4 hrs/day with an average of 9h26min.
Proven and potential beneﬁts of NIV in CF are well known. Indications and
contraindications have not been yet deﬁned but, in our opinion, NIV can be used
in severe lung damage with positive results. Nevertheless a prudent and a low-
pressures-approach is mandatory.
393* CPAP for atelectasis in bronchopulmonary aspergillosis
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CPAP is a valid tool in various conditions. Physiotherapy (pt) often takes advantages
by PAP devices for different purposes, such as lung recruitment manoeuvres,
restrictive status and airway patency. However, there are no guidelines on how
and for how long patients need to be treated with CPAP, neither clinical indications
for cystic ﬁbrosis.
A 12 years old CF girl (FEV1 120–140% pred.) with a right lobar atelectasis started
ab therapy i.v. on May 3rd 2010 with ceftazidime and tobramycin; pt program after
this new ﬁnding consisted in PEP-Mask twice a day with 2.0mm resistor and
range pressure around 15−20 cmH2O for 15 min/session, b2 pMDI (2 puff/twice a
day), DNase (1 vial/day). On May 5th i.v. therapy was changed with meropenem,
levoﬂoxacin and methylprednisolone due to increased PCR. On May 17th X-ray
showed the same atelectasic area. Transferred in stable clinical conditions to our hos-
pital, laboratory found high IgE level for Aspergillus suggesting bronchopulmonary
aspergillosis then treated successfully with steroids and itraconazole (already in
therapy). Hence we introduced then CPAP delivered by nasal mask at 10 cmH2O
for 8 hrs/day (4 hrs during afternoon and 4 hrs overnight consecutively). Patient
tolerated well the CPAP treatment. After 8 days the X-ray showed a signiﬁcant
resolution and patient was discharged. PEP-Mask continued home in the same
modality. The follow-up X-ray, two months later, showed disappearance of lung
atelectasis.
CPAP therapy was determinant in accelerating this process and it resulted as a valid
tool for improving lobar atelectasis. Its application is feasible in this population.
Further studies are urgently needed to guide our management.
394 Cystic ﬁbrosis liver disease: an emerging clinical issue showing
a multifactorial pathogenesis
F. Alghisi1, E. Montemitro1, S. Bella1, V. Lucidi1. 1Bambino Gesu` Children’s
Hospital − IRCCS, Rome, Italy
Objectives: Cystic Fibrosis Liver Disease (CFLD) has gained clinical relevance
with the decreasing mortality from extrahepatic causes. Several factors have been
associated with the development of CFLD, as pancreatic insufﬁciency and severe
genotype.
Methods: We discuss clinical and diagnostic implications of CFLD describing two
case-reports. Case 1: a six-year-old male with a positive newborn screening for
CF but a negative sweat test. He had pancreatic sufﬁciency and he was carrier of
the F508del mutation at the ﬁrst-level genetic analysis. He complained of recurrent
episodes of bronchitis, treated with several antibiotic courses. An unexpected liver
involvement (moderate steatosis, regenerative nodules) was occasionally detected
at the age of 4 years. We performed the extensive genetic analysis that identiﬁed a
second CFTR mutation (R31E), supporting a CF diagnosis. Case 2: a ﬁve-year-old
female having constantly normal sweat test values and positive CFTR gene analysis
(G542X/F1074R). She had pancreatic sufﬁciency but she was treated with enteral
nutrition because of a failure to thrive. A liver involvement was identiﬁed since the
ﬁrst month of life because she had recurrent hypertransaminasemia. For this reason,
she underwent a liver biopsy that showed periductal damage and biliary stasis.
Conclusions: CFLD may start early in life of CF patients. It can also occur in
patients with pancreatic sufﬁciency. The clinical expression may be inﬂuenced by
non-genetic factors, as malnutrition and antibiotic courses. A possible role of genetic
modiﬁers is suggested by the detection of a normal sweat test. Their identiﬁcation
could allow prophylactic strategies.
